About lab
This model of the use of chimeric antigen receptor (CAR)-T cell therapy in the treatment of solid tumours is described in the article:'Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override. It can be used to explore immune response dynamics and compare pathway-level behavior across conditions.
Runtime
Duration10
Comms Step1
Runs
Total0
Completed0
Failed0
Metadata
Packageleon-triana2021-competition-between-tumour-cells-and-dual-target
Created2026-05-15
Updated2026-05-15
immunologysbmlbiomodels_ebifaithfulcuratedvisualisation
Manifest
{
"io": {
"inputs": [
{
"name": "initial_car_t_cells_on_tumour",
"label": "Initial Car T Cells On Tumour",
"units": "native source value",
"default": 0,
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.initial_car_t_cells_on_tumour",
"description": "Initial Car T Cells On Tumour. Sets the initial value of bundled SBML species `CAR_T_cells_on_tumour`."
},
{
"name": "initial_car_t_cells_off_tumour",
"label": "Initial Car T Cells Off Tumour",
"units": "native source value",
"default": 200000000,
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.initial_car_t_cells_off_tumour",
"description": "Initial Car T Cells Off Tumour. Sets the initial value of bundled SBML species `CAR_T_cells_off_tumour`."
},
{
"name": "initial_tumour_cells",
"label": "Initial Tumour Cells",
"units": "native source value",
"default": 33500000000,
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.initial_tumour_cells",
"description": "Initial Tumour Cells. Sets the initial value of bundled SBML species `Tumour_cells`."
},
{
"name": "initial_cells",
"label": "Initial Cells",
"units": "native source value",
"default": 25000000000,
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.initial_cells",
"description": "Initial Cells. Sets the initial value of bundled SBML species `B_cells`."
},
{
"name": "tumour_death_rate",
"label": "Tumour Death Rate",
"units": "unit_3",
"default": 2.5e-10,
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.tumour_death_rate",
"description": "Tumour Death Rate. Sets bundled SBML parameter `alpha_2`."
}
],
"outputs": [
{
"name": "car_t_cells_on_tumour",
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.car_t_cells_on_tumour"
},
{
"name": "car_t_cells_off_tumour",
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.car_t_cells_off_tumour"
},
{
"name": "car_t_cells_total",
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.car_t_cells_total"
},
{
"name": "tumour_cells",
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.tumour_cells"
},
{
"name": "cells",
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.cells"
},
{
"name": "state",
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.state"
},
{
"name": "summary",
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.summary"
},
{
"name": "species_labels",
"maps_to": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.species_labels"
}
]
},
"title": "Leon-Triana2021 - Competition between tumour cells and dual-target CAR T-cells Lab",
"models": [
{
"path": "owned/models/immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model",
"alias": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model",
"provenance": {
"owned_path": "owned/models/immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model"
}
},
{
"path": "owned/models/visualisation",
"alias": "visualisation",
"provenance": {
"owned_path": "owned/models/visualisation"
}
}
],
"wiring": [
{
"to": [
"visualisation.immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model_state"
],
"from": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.state"
},
{
"to": [
"visualisation.immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model_summary"
],
"from": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.summary"
},
{
"to": [
"visualisation.immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model_species_labels"
],
"from": "immunology_sbml_leon_triana2021_competition_between_tumour_cells_biomd0000001014_model.species_labels"
}
],
"runtime": {
"duration": 10,
"initial_inputs": {},
"communication_step": 1
},
"description": "This model of the use of chimeric antigen receptor (CAR)-T cell therapy in the treatment of solid tumours is described in the article:'Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override. It can be used to explore immune response dynamics and compare pathway-level behavior across conditions.",
"schema_version": "2.0"
}Sign in to start your own run. Public-lab history stays visible here.
Select a run from History to view its results.